By Dean Seal
Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy.
The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year.
The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage.
Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 16, 2024 09:38 ET (14:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。